Gene therapies are being redesigned with synthetic biological circuits that switch therapeutic genes on and off in the right cells at the right time. Current gene therapies often struggle to control where and how strongly a therapeutic gene is expressed once inside the body. A gene that works in the liver might cause harm in the heart; a gene that stays active too long could trigger side effects. This multidisciplinary hub—bringing together teams from Edinburgh, Oxford, Imperial College London, and the Beatson Cancer Research Institute—aims to build a toolkit of engineered genetic control systems. These systems will regulate transgene expression and improve delivery into cells, addressing two fundamental bottlenecks in the field. If successful, the research could make gene therapies safer and more effective for three major application areas: oncology, cardiovascular disease, and rare genetic disorders. Better control over gene expression means treatments could be tailored to specific tissues, reducing off-target effects and improving patient outcomes. The global gene therapy market, valued at USD 6.36 billion in 2022, is projected to reach USD 40.39 billion by 2031—this work directly targets the engineering challenges that currently limit that growth.
View original technical description
This application addresses engineering biology for biomedicine specifically in the area of gene therapy (GT). Cell and gene therapies (CGTs) have the potential to revolutionise healthcare and are arguably the most exciting areas of biotechnology both due to recent progress and future possibilities. Gene therapy is a technique that modifies a person's genes to treat or cure disease. Gene therapies can work by several mechanisms: Replacing a disease-causing gene with a healthy copy of the gene, inactivating a disease-causing gene that is not functioning correctly or introducing a new or modified gene to help treat a disease. The main delivery mechanisms for GTs are viral vectors including AAV and lentivirus where the virus has been modified to remove their ability to cause infectious disease and free up space in their genome for insertion of genetic "cargo" enabling therapeutic genes to be carried into human cells. The emergence of CGTs has played a major role in reshaping the biopharmaceutical industry and has transformed the treatment paradigm of a range of life-threatening and rare diseases. The global gene therapy market value was USD 6.36 billion in 2022 driven by the increasing identification and prevalence of genetic disorders across the globe. The market size is anticipated to grow at a CAGR of 22.8% during 2023-2031 to achieve a value of USD 40.39 billion by 2031. For gene therapies to be effective and safe they need to express the transgene in the right tissue, at the right level, for the right amount of time and to be delivered efficiently to the correct tissues. Engineering Biology is the perfect technology to address these challenges and our mission is to use Engineering Biology to develop a series of engineered genetic control systems for use in Gene Therapies both in the control of expression of the therapeutic transgene but also in the development of enhanced delivery systems. This Hub will bring together a multidisciplinary team from the Universities of Edinburgh, Oxford, Imperial College London and the Beatson Cancer Research Institute to develop a new suite of engineering biology tools for control of transgene expression, delivery into cells and test them in three application spaces - oncology, cardiovascular disease and rare diseases.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know